Dexmedetomidine in Spinal Anesthesia
Hemodynamic Effect of Dexmedetomidine on Heavy Bupivacaine Spinal Anesthesia
1 other identifier
interventional
74
1 country
1
Brief Summary
Patients were randomized into two groups, A group and B group. A group and B group patients are injected intravenous dexmedetomidine after intrathecal injection (IT) of heavy bupivacaine and injected intravenous dexmedetomidine before IT of heavy bupivacaine, respectively. The investigators will compare of hemodynamics and patient's comfortability between two groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 22, 2014
CompletedFirst Posted
Study publicly available on registry
June 4, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2015
CompletedResults Posted
Study results publicly available
September 26, 2016
CompletedSeptember 26, 2016
August 1, 2016
1.3 years
May 22, 2014
December 10, 2015
August 3, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of Hypotension
We compare incidence rate of hypotension during infusion of dexmedetomidine
up to 3 hours
Secondary Outcomes (1)
Patient's Anxiety
up to 3 days
Study Arms (2)
Dexmedetomidine
EXPERIMENTALIV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
Dexmedetomidine with heavy bupivacaine
ACTIVE COMPARATORIV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
Interventions
Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
Dexmedetomidine infusion after IT of heavy bupivacaine
Eligibility Criteria
You may qualify if:
- aged patients
- orthopedic operation undergoing spinal anesthesia
You may not qualify if:
- more than American society of anesthesiologists classification 3
- hypertension
- diabetes mellitus
- heart disease (bradycardia, atrioventricular block)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Inje Universitylead
Study Sites (1)
Inje University, Haeundae paik hospital
Busan, 612-896, South Korea
Related Publications (1)
Kang E, Lee KH, Jeon SY, Lee KW, Ko MJ, Kim H, Kim YH, Jung JW. The timing of administration of intravenous dexmedetomidine during lower limb surgery: a randomized controlled trial. BMC Anesthesiol. 2016 Nov 21;16(1):116. doi: 10.1186/s12871-016-0282-2.
PMID: 27871236DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
We did not assess the differences among the groups regarding postoperative analgesic consumption and the duration of sensory or motor bloakade produced by spinal anesthesia with dexmedetomidine infusion.
Results Point of Contact
- Title
- Ki Hwa Lee
- Organization
- Haeundae paik hospital, Inje University
Study Officials
- PRINCIPAL INVESTIGATOR
Ki Hwa Lee, MD
Inje University Haeundae Paik Hospital
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
May 22, 2014
First Posted
June 4, 2014
Study Start
March 1, 2014
Primary Completion
July 1, 2015
Study Completion
July 1, 2015
Last Updated
September 26, 2016
Results First Posted
September 26, 2016
Record last verified: 2016-08
Data Sharing
- IPD Sharing
- Will share
De-identified individual participant data for all primary and secondary outcome measures will be made available within 3 years of study completion.